Michele Maio
University of Siena
4 papers in the Anchorcite directory, published between 2011 and 2017, cited 24,035 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Cutaneous Melanoma Detection and Management · 4 papers
- Melanoma and MAPK Pathways · 4 papers
Frequent co-authors
- Vanna Chiarion‐Sileni · 3 papers
- Jean‐Jacques Grob · 3 papers
- Dirk Schadendorf · 3 papers
- Piotr Lukasz Rutkowski · 3 papers
- Paolo A. Ascierto · 3 papers
- Georgina Venetia Long · 3 papers
- Jedd D. Wolchok · 3 papers
- Célèste Lebbé · 3 papers
Papers
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab…
- Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a…
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study…
Metadata from OpenAlex (CC0).